GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PT Indofarma Tbk (ISX:INAF) » Definitions » Capex-to-Revenue

PT Indofarma Tbk (ISX:INAF) Capex-to-Revenue : 0.03 (As of Sep. 2023)


View and export this data going back to 2001. Start your Free Trial

What is PT Indofarma Tbk Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

PT Indofarma Tbk's Capital Expenditure for the three months ended in Sep. 2023 was Rp-2,057.51 Mil. Its Revenue for the three months ended in Sep. 2023 was Rp81,736.85 Mil.

Hence, PT Indofarma Tbk's Capex-to-Revenue for the three months ended in Sep. 2023 was 0.03.


PT Indofarma Tbk Capex-to-Revenue Historical Data

The historical data trend for PT Indofarma Tbk's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PT Indofarma Tbk Capex-to-Revenue Chart

PT Indofarma Tbk Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.01 0.01 0.01 0.01

PT Indofarma Tbk Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 -0.03 - 0.01 0.03

Competitive Comparison of PT Indofarma Tbk's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, PT Indofarma Tbk's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PT Indofarma Tbk's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PT Indofarma Tbk's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where PT Indofarma Tbk's Capex-to-Revenue falls into.



PT Indofarma Tbk Capex-to-Revenue Calculation

PT Indofarma Tbk's Capex-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-13475.983) / 1144108.231
=0.01

PT Indofarma Tbk's Capex-to-Revenue for the quarter that ended in Sep. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-2057.511) / 81736.853
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PT Indofarma Tbk  (ISX:INAF) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


PT Indofarma Tbk Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of PT Indofarma Tbk's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


PT Indofarma Tbk (ISX:INAF) Business Description

Traded in Other Exchanges
N/A
Address
Jalan Indofarma No. 1, Cikarang Barat, Jawa Bara, Bekasi, IDN, 17530
PT Indofarma Tbk is a specialty and generic drug manufacturing company. The company has four business segments - Medicine, Medical Devices and others, Pharmaceutical Engineering, and Aliansi Strategis Segment. The Medicine business segment includes drug production, marketing and distribution and sales. The Medical Device Segment includes medical devices and other products. The Pharmaceutical Engineering Segment includes the sale and maintenance of packaging machines for the pharmaceutical industry to external parties.

PT Indofarma Tbk (ISX:INAF) Headlines

No Headlines